Skip to main content
Immunovant, Inc. logo

Immunovant, Inc. — Investor Relations & Filings

Ticker · IMVT ISIN · US45258J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 566 across all filing types
Latest filing 2026-05-20 Annual Report
Country US United States of America
Listing US IMVT

About Immunovant, Inc.

https://immunovant.com/

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. The company develops monoclonal antibodies designed to treat a range of autoimmune conditions. Its therapeutic approach focuses on targeting the neonatal Fc receptor (FcRn) to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which are central drivers of many autoimmune diseases. The company's pipeline is centered on developing anti-FcRn antibodies, including its product candidate IMVT-1402, for subcutaneous administration.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2026
2026-05-20 English
8-K
Regulatory Filings Classification · 87% confidence The document is a U.S. SEC Form 8-K “Current Report” pursuant to the Securities Exchange Act of 1934. It reports the issuance of a press release of financial results and furnishes that release as an exhibit. It does not itself contain the full earnings data beyond the press release reference, nor is it an annual or quarterly report. Therefore, it is a general regulatory filing and falls under the RNS category.
2026-05-20 English
4 - Immunovant, Inc. (0001764013) (Issuer)
Director's Dealing
2026-03-20 English
4 - IMMUNOVANT, INC. (0001764013) (Filer)
Director's Dealing
2026-02-27 English
10-Q Filing
Interim / Quarterly Report Q3 2026
2026-02-06 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is Item 2.02, which states that the company issued a press release announcing financial results for the fiscal third quarter and nine months ended December 31, 2025. The document includes the press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 3596 characters, which is relatively short and consistent with a current report filing rather than a full interim or quarterly report. The document explicitly states it is furnishing a press release and does not file the financial results themselves. Therefore, this is an Earnings Release (ER) type document, as it is the initial announcement of quarterly/periodical financial results (key highlights only).
2026-02-06 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.